Expanded Access Protocol of Givosiran for Patients With Acute Hepatic Porphyria

Acute Hepatic Porphyria Clinical Trial

Official title:
Expanded Access Protocol of Givosiran for Patients With Acute Hepatic Porphyria (AHP)

Status Approved for marketing

Clinical Trial Summary

The purpose of this study is to provide expanded access of givosiran to patients with Acute Hepatic Porphyria (AHP).

Clinical Trial Description

Choosing to participate in an expanded access program is an important personal decision. Talk with your doctor and family members or friends about deciding to join a research study. To learn more about this study, please have your doctor contact the study research staff using the Contacts provided. For general information, see the link provided in More Information. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04056481
Study type	Expanded Access
Source	Alnylam Pharmaceuticals
Contact
Status	Approved for marketing
Phase

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03338816` - ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)	Phase 3
Terminated	`NCT03547297` - INSIGHT-AHP: A Study to Characterize the Prevalence of Acute Hepatic Porphyria (AHP) in Patients With Clinical Presentation and History Consistent With AHP
Not yet recruiting	`NCT04923516` - Prevalence of Acute Hepatic Porphyria
Recruiting	`NCT05344599` - Evaluating the Prevalence of Acute Hepatic Porphyria in Postural Tachycardia Syndrome
Completed	`NCT02240784` - EXPLORE: A Natural History Study of Acute Hepatic Porphyria (AHP)
Recruiting	`NCT04883905` - ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)